In a phase IIa study (NCT02083354) of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma treated with dabrafenib (150 mg twice daily) with trametinib (2 mg once daily), treatment sequencing results were collected. The gene discussed is BRAF; the disease is cutaneous melanoma.